Francisella tularensis

Background

Clinical Features[1]

  • Ulceroglandular: MC form
    • Ulcer forms at the site of bacteria inoculation plus lymphadenopathy
  • Glandular
    • Lymphadenopathy
  • Oculoglandular
    • Occurs when bacteria inoculates the eye
  • Oropharyngeal
    • Pharyngitis, tonsilitis
  • Pneumonic
    • Most serious
    • Cough, dyspnea, chest pain
  • Typhoidal


Antibiotic Sensitivities[2]

Category Antibiotic Sensitivity
PenicillinsPenicillin GX1
Penicillin VX1
Anti-Staphylocccal PenicillinsMethicillinX1
Nafcillin/OxacillinX1
Cloxacillin/Diclox.X1
Amino-PenicillinsAMP/AmoxX1
Amox-ClavX1
AMP-SulbX1
Anti-Pseudomonal PenicillinsTicarcillinX1
Ticar-ClavX1
Pip-TazoX1
PiperacillinX1
CarbapenemsDoripenemX1
ErtapenemX1
ImipenemX1
MeropenemX1
AztreonamX1
FluroquinolonesCiprofloxacinX1
OfloxacinX1
PefloxacinX1
LevofloxacinX1
MoxifloxacinX1
GemifloxacinX1
GatifloxacinX1
1st G CephaloCefazolinX1
2nd G. CephaloCefotetanX1
CefoxitinX1
CefuroximeX1
3rd/4th G. CephaloCefotaximeX1
CefizoximeX1
CefTRIAXoneX1
CeftarolineX1
CefTAZidimeX1
CefepimeX1
Oral 1st G. CephaloCefadroxilX1
CephalexinX1
Oral 2nd G. CephaloCefaclor/LoracarbefX1
CefproxilX1
Cefuroxime axetilX1
Oral 3rd G. CephaloCefiximeX1
CeftibutenX1
Cefpodox/Cefdinir/CefditorenX1
AminoglycosidesGentamicinS
TobramycinS
AmikacinS
ChloramphenicolS
ClindamycinX1
MacrolidesErythromycinX1
AzithromycinX1
ClarithromycinX1
KetolideTelithromycinX1
TetracyclinesDoxycyclineS
MinocyclineX1
GlycylcyclineTigecyclineX1
DaptomycinR
Glyco/LipoclycopeptidesVancomycinX1
TeicoplaninX1
TelavancinX1
Fusidic AcidX1
TrimethoprimX1
TMP-SMXS
Urinary AgentsNitrofurantoinX1
FosfomycinX1
OtherRifampinS
MetronidazoleR
Quinupristin dalfoppristinX1
LinezolidR
ColistimethateX1

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

Table Overview

See Also

References

  1. CDC. Tularemia. 2015
  2. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.